Melanoma-associated antigen 3 peptide-HLA class I complex (MAGE-A3/HLA-I)

The Melanoma-associated antigen 3 (MAGE-A3) peptide-HLA class I complex is a highly specific tumor target formed when intracellular MAGE-A3 proteins are degraded by the proteasome and their resulting peptides are loaded onto Human Leukocyte Antigen (HLA) class I molecules for surface presentation. As a member of the cancer-testis antigen (CTA) family, MAGE-A3 is typically expressed only in male germ cells (which lack HLA expression) and various malignancies, making the pMHC complex an ideal target for immunotherapy (1.4.1, 1.4.2). Common immunogenic peptides include EVDPIGHLY presented by HLA-A*01 and KVAELVHFL presented by HLA-A*02 (1.1.1, 1.3.1). Biologically, MAGE-A3 promotes tumor survival by forming complexes with TRIM28 to enhance the degradation of tumor suppressors like p53 and AMPK (1.4.1, 1.4.4). Therapeutic strategies targeting this complex include TCR-engineered T cells (TCR-T), peptide vaccines, and bispecific molecules like ImmTACs. While early clinical trials showed promise in inducing tumor regression, significant safety challenges emerged, most notably fatal cardiogenic shock caused by TCR cross-reactivity with a similar peptide from the muscle protein Titin (1.3.1, 1.3.3). Additionally, neurotoxicity has been observed due to unexpected cross-recognition of MAGE-A12 in the central nervous system (1.3.2, 1.3.5). Current development focuses on enhancing TCR specificity and utilizing advanced preclinical screening, such as iPSC-derived cardiomyocytes, to mitigate off-target risks (1.3.3, 1.3.5).

Other names

MAGE-A3 pMHCMAGE-A3/HLA-A*01 complexMAGE-A3/HLA-A*02 complexMAGE-A3/HLA-A1 complexMAGE-A3/HLA-A2 complexMelanoma-associated antigen 3-derived peptide presented by MHC class I

Drugs targeting this complex, such as TCR-engineered T cells (TCR-T) or bispecific T-cell engagers (ImmTACs), bind specifically to the MAGE-A3 peptide presented within the HLA class I groove. This binding triggers T-cell receptor (TCR) signaling, leading to the release of cytotoxic granules (perforin and granzymes) and pro-inflammatory cytokines (IFN-gamma, TNF-alpha), which results in the selective lysis of MAGE-A3-expressing tumor cells.